slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 67,051-67,080
Pages 3,679
Rows per page 30
Component
67,051-67,080 of 110,355
01
Background image features branded ponchos for the NYC Marathon.Stran & Company | Investor Presentation Deck | 31 slides · Stran & Company
Pitch deck Investor relations 1 hit
07
The slide uses a 2x5 grid layout to present company performance and market data.Stran & Company | Investor Presentation Deck | 31 slides · Stran & Company
Pitch deck Investor relations 1 hit
08
The chart uses a bar-vertical style with a secondary visual element (the teal triangle) to emphasize growth.Stran & Company | Investor Presentation Deck | 31 slides · Stran & Company
Pitch deck Investor relations Beat · Market Size1 hit
17
The slide uses a map of the USA to anchor the TAM figure and lists specific industry segments with their respective market sizes.Stran & Company | Investor Presentation Deck | 31 slides · Stran & Company
Pitch deck Investor relations 1 hit
20
The chart uses alternating blue and teal bars for annual data, with a distinct orange bar for the 2022 half-year figure.Stran & Company | Investor Presentation Deck | 31 slides · Stran & Company
Pitch deck Investor relations Beat · Financial Highlights1 hit
15
The table tracks specific expense categories (Marketing/Growth, Site Strategy) and their resulting EPS impact.Synchrony Financial | Results Presentation Deck | 17 slides · Synchrony
Conference presentation Investor relations 1 hit
16
The table reconciles Loan receivables, Purchase volume, Average active accounts, and New Accounts.Synchrony Financial | Results Presentation Deck | 17 slides · Synchrony
Conference presentation Investor relations 1 hit
17
The slide provides a detailed breakdown of CECL transition adjustments and allowance for credit losses.Synchrony Financial | Results Presentation Deck | 17 slides · Synchrony
Conference presentation Investor relations 1 hit
05
Includes a patient quote and clinical imagery to emphasize the severity of the condition.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide presents interim Phase 1b data from a study by Maurer et al. (EAACI, 2022).Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a combination of a bulleted list for qualitative benefits and a table for quantitative selectivity data.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Product1 hit
10
The chart displays multiple dose regimens (200mg QD, 200mg BID, 500mg QD FED, 400mg BID) with error bars representing standard deviation.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
12
The chart tracks neutrophil levels from Day 1 to Day 70/EOS, with an 'End of treatment' marker at Day 14.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
13
Includes a disclaimer about the reliability of cross-study comparisons.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
14
Includes two line charts with error bars representing mean +/- SD. LLOQ marked on the absolute chart.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
15
The schematic illustrates a dose-escalation study with three cohorts of 10 patients each, followed by a 4-week follow-up period.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
16
Data presented as Mean ± SD. Logarithmic scale on Y-axis.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
17
The slide combines mechanistic biological data (Maun et al.) with clinical trial results (Cahill et al., NEJM) to justify targeting mast cells in severe asthma.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Why NowLoop · Why Now1 hit
18
The slide outlines a randomized, placebo-controlled trial structure with specific weeks and days for allergen challenges and measurements.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
19
The slide uses a timeline-based visualization to show clinical progress and pairs it with financial status.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · The Ask1 hit
06
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
09
Clinical trial design slide for Tonix Pharmaceuticals.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
Slide 10 of a corporate presentation deck.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
Slide 13 of a Tonix Pharmaceuticals presentation.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
Includes clinical trial status and mechanism of action highlights.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a two-column layout to contrast the disease profile with the development program status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
Includes a comparison of three generations of CD40L antibodies and a structural diagram of the antibody.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit